Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart fix may stop migraines: new trial tests Hole-Closing procedure

NCT ID NCT07170176

Symptom relief Sponsor: First Affiliated Hospital Xi'an Jiaotong University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether closing a small hole in the heart (called a PFO) can reduce migraine attacks and improve brain function. Researchers will compare 150 adults with migraines and a PFO who get the closure procedure to those who don't. The goal is to see if the procedure cuts monthly migraine days and eases pain.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Percutaneous patent foramen ovale closure device
What this could lead to
If it works, this could point toward a non-drug treatment for migraines in people with a common heart defect.
What could go wrong
This is a small, early-stage study with no control group for the procedure, so results may not be conclusive. The procedure itself carries risks like bleeding or device complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults aged 18 to 60 years. 2. Diagnosed with patent foramen ovale (PFO) with significant right-to-left shunt. 3. For the case group: Diagnosis of migraine (with or without aura) according to the International Classification of Headache Disorders (ICHD-3). 4. For the control group: No history of migraine. 5. Willing and able to provide written informed consent. 6. Education level of primary school or higher. Exclusion Criteria: 1. Patients with a history of PFO closure or other migraine-related surgical treatments; 2. Patients with other severe cardiac or neurological diseases, mental disorders, or psychological conditions; 3. Patients with contraindications to closure surgery or MRI scans (e.g., severe infection, coagulation dysfunction, cardiac pacemakers, aneurysm clips, metallic foreign bodies in the eye, non-removable metal dentures, etc.); 4. Patients unable to complete migraine symptom assessments or imaging examinations due to other reasons.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Migraine disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

congenital cardiovascular shunt migraine disorder patent foramen ovale

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Migraine disorders Patent foramen ovale Right-to-left shunt, cardiac

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Luoyang Central Hospital

    RECRUITING

    Luoyang, Henan, 471009, China

  • The Second Hospital of Tianjin Medical University

    RECRUITING

    Tianjin, Tianjin Municipality, 300211, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.